Conjugated linoleic acid vesicle for preventing and treating alopecia and application of conjugated linoleic acid vesicle
By constructing conjugated linoleic acid nanovesicles, combining phospholipids and vitamin E polyethylene glycol succinate, and modifying arginine on the surface, the side effects and poor efficacy of existing hair loss treatment drugs have been solved, and the problem of intravenous treatment of hair loss has been achieved. Effective treatment of androgen-derived hair loss and the relief of hair follicle cell aging significantly promote hair regeneration.
Patent Information
- Application Number
- CN202411144899.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-20
AI Technical Summary
Existing hair loss treatment drugs have side effects, inapplicability and poor efficacy, especially since finasteride is not suitable for women and has long-term use causes sexual dysfunction, minoxidil contains organic solvents to cause allergies and adverse skin reactions. Moreover, the mechanism of action is single, making it difficult to effectively treat hair follicle cell aging.
Conjugated linoleic acid is used as the capsule material and active ingredient to construct nanovesicles, combine phospholipids and vitamin E polyethylene glycol succinate, and modify arginine on the surface to form conjugated linoleic acid nanovesicles. Nanocarriers for hair loss treatment improve the percutaneous penetration and retention behavior of drugs, and enhance the accumulation and targeting of hair follicle sites.
Improve the effect of hair loss treatment, and through the preparation method of conjugated linoleic acid nanovesicles, it achieves good therapeutic effects in androgen-derived hair loss, alleviates the aging problem of hair follicle cells, and significantly promotes hair in both men and women. regeneration.
Smart Images

Figure BDA0005001942630000121 
Figure HDA0005001942640000011 
Figure HDA0005001942640000012
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and in particular relates to a conjugated linoleic acid vesicle for preventing and treating hair loss and an application thereof. Background Art
[0002] As a global disease, hair loss has seriously affected the mental health and quality of life of more than 50% of the population, and it troubles a number of men and women at the same time. In recent years, with the intensification of mental stress and environmental pollution, the prevalence of hair loss has increased year by year.
[0003] At present, the main drugs for the treatment of hair loss are oral finasteride and topical minoxidil. Among them, finasteride is an oral preparation and is generally not used to treat female hair loss. Long-term use can cause side effects such as sexual dysfunction and breast hyperplasia. Minoxidil topical preparations usually contain a large amount of organic solvents such as propylene glycol, which makes some patients unable to use it due to allergies. At the same time, there are problems such as increased adverse skin reactions with prolonged use, which greatly reduces patient compliance. In addition, hair loss is also affected by many factors, and the mechanism of action of existing drugs is relatively single, so it is difficult to achieve good therapeutic effects. For example, cell senescence plays an important role in the occurrence and development of hair loss. However, to date, there is a lack of effective hair loss treatment strategies for hair follicle cell senescence.
[0004] Conjugated linoleic acid is a polyunsaturated fatty acid with multiple pharmacological activities, including anti-adipogenesis, anti-atherosclerosis, restoration of vascular function, anti-inflammatory and anti-oxidation. CN 108967665A discloses a hair-increasing agent containing conjugated linoleic acid, which can increase the density of hair follicles by promoting cell proliferation, activating hair follicles, etc. However, free conjugated linoleic acid cannot effectively accumulate in the hair follicles, nor can it form a drug reservoir, resulting in limited effect of treating hair loss. In addition, conjugated linoleic acid can usually only self-assemble to form nanovesicles in an alkaline environment, but the normal pH value of the skin is weakly acidic, and the alkaline system is not only not conducive to the absorption of active ingredients, but also destroys the barrier function and flora balance of the skin after long-term use, leading to skin damage and the occurrence of diseases. Summary of the invention
[0005] The present invention intends to construct nanovesicles using conjugated linoleic acid as the main capsule material. In the treatment of hair loss, conjugated linoleic acid can play the dual role of capsule material and active ingredient at the same time. Conjugated linoleic acid not only has pharmacological activities such as promoting hair follicle cell proliferation and migration, alleviating the occurrence of hair follicle cell aging, but also the constructed conjugated linoleic acid nanovesicles can be used as nanocarriers for treating hair loss and loaded with different hair loss treatment drugs. Conjugated linoleic acid vesicles can improve the transdermal penetration and retention behavior of conjugated linoleic acid and the drugs carried therein, enhance the accumulation of conjugated linoleic acid and drugs in the hair follicle area and the hair follicle targeting effect, thereby improving the hair loss treatment effect of the drug.
[0006] The first aspect of the present invention aims to provide a nanovesicle.
[0007] The second aspect of the present invention aims to provide a method for preparing the above-mentioned nanovesicles.
[0008] The third aspect of the present invention aims to provide applications of the above-mentioned nanovesicles.
[0009] The fourth aspect of the present invention aims to provide a product comprising the above-mentioned nanovesicles.
[0010] The fifth aspect of the present invention aims to provide a method for preparing the above-mentioned product.
[0011] The technical solution adopted by the present invention is:
[0012] A first aspect of the present invention provides a nanovesicle, wherein raw materials for preparing the nanovesicle include conjugated linoleic acid, phospholipids, and vitamin E polyethylene glycol succinate.
[0013] Preferably, the phospholipid is one or more of soybean lecithin, egg yolk lecithin, hydrogenated lecithin, distearoylphosphatidylcholine, dioleoyl lecithin, distearoylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine, dimyristoyl lecithin, dipalmitoylphosphatidylcholine, and dioleoylphosphatidylcholine.
[0014] Preferably, the mass ratio of the conjugated linoleic acid, phospholipids, vitamin E polyethylene glycol succinate and arginine is 2:0.1-0.9:0.1-0.9.
[0015] Preferably, the raw material for preparing the nanovesicles further includes arginine.
[0016] Preferably, the mass ratio of the conjugated linoleic acid, phospholipids, vitamin E polyethylene glycol succinate and arginine is 2:0.1-0.9:0.1-0.9:0.1-5.
[0017] The second aspect of the present invention provides a method for preparing the above-mentioned nanovesicles, comprising the following steps:
[0018] S1: Conjugated linoleic acid, phospholipids and vitamin E polyethylene glycol succinate are weighed separately, mixed and dissolved in an organic solvent to obtain a nanovesicle solution A.
[0019] Preferably, the method further comprises:
[0020] S2: adding solution A to the arginine solution and mixing them to obtain a nanovesicle solution containing arginine.
[0021] Preferably, the mass volume ratio of the mixture to the organic solvent is 60-120 mg / mL.
[0022] Preferably, the organic solvent includes at least one of anhydrous ethanol, butylene glycol and propylene glycol.
[0023] Preferably, the arginine solution is prepared by adding arginine into a solvent to obtain the arginine solution.
[0024] Preferably, the mass volume ratio of arginine to solvent is 0.1-12.5 mg / mL.
[0025] Preferably, the solvent for the arginine includes but is not limited to water and a buffer solution.
[0026] Preferably, the buffer comprises PBS buffer or HEPES buffer.
[0027] Preferably, the pH of the buffer solution is 6-8.
[0028] Preferably, the mixed solution in step S2 is added dropwise to the arginine solution.
[0029] Preferably, the mixing time in step S2 is 30 min to 60 min, the rotation speed is 500 rpm to 1000 rpm, and the temperature is 10° C. to 30° C.
[0030] The third aspect of the present invention provides the use of the nanovesicles described in the second aspect of the present invention in the preparation of products for hair growth and / or prevention and treatment of hair loss.
[0031] Preferably, the hair loss includes partial hair loss, total hair loss or systemic hair loss caused by androgenic alopecia, seborrheic alopecia, anagen effluvium, telogen effluvium, drug-induced alopecia, alopecia areata, tinea capitis or hypotrichosis.
[0032] Preferably, the products include medicines and daily chemicals.
[0033] Preferably, the daily chemical products include but are not limited to hair growth liquid, hair tonic, hair conditioner, shampoo head, hair cleaning foam, hair oil, hair dryer, hair dye, hair gel, hair glaze, hair moisturizer, hair mask, hair cream, eyebrow growth agent, eyelash growth agent, eyelash nutrition agent.
[0034] Preferably, the product also includes auxiliary materials.
[0035] Preferably, the excipients include at least one of surfactants, thickeners, cosolvents, pearlescent agents, conditioners, preservatives, chelating agents, buffers, flavors, pigments, diluents, wetting agents, adhesives, disintegrants, lubricants, color or odor regulators, solvents, solubilizers, emulsifiers, antioxidants, metal complexing agents, inert gases, local analgesics, pH regulators, and isotonic or isotonic regulators.
[0036] Preferably, the dosage form of the product includes but is not limited to granules, granules, capsules, tablets, sprays, lotions, ointments, patches, injections, emulsions, aerosols, drops, gels, microneedles, controlled-release agents, and sustained-release agents.
[0037] Preferably, the administration of the product includes subcutaneous administration, intramuscular administration, intraperitoneal administration, intravenous injection, infusion, oral administration, nasal administration or other local administration, or a combination of any of the above administration methods.
[0038] The fourth aspect of the present invention provides a product, wherein the product comprises the nanovesicles described in the first aspect of the present invention.
[0039] Preferably, the product further comprises one or more other drugs for treating hair loss.
[0040] Preferably, the other drugs include minoxidil, finasteride, dutasteride, spironolactone tablets, cyproterone acetate, and / or clobetasol propionate or pharmaceutically acceptable salts thereof.
[0041] Preferably, the mass ratio of conjugated linoleic acid to other drugs in the nanovesicles is 1:0.01-1.5.
[0042] Preferably, the product further comprises auxiliary materials.
[0043] Preferably, the excipients include at least one of surfactants, thickeners, cosolvents, pearlescent agents, conditioners, preservatives, chelating agents, buffers, flavors, pigments, diluents, wetting agents, adhesives, disintegrants, lubricants, color or odor regulators, solvents, solubilizers, emulsifiers, antioxidants, metal complexing agents, inert gases, local analgesics, pH regulators, and isotonic or isotonic regulators.
[0044] Preferably, the dosage form of the product includes but is not limited to granules, granules, capsules, tablets, sprays, lotions, ointments, patches, injections, emulsions, aerosols, drops, gels, microneedles, controlled-release agents, and sustained-release agents.
[0045] Preferably, the administration of the product includes subcutaneous administration, intramuscular administration, intraperitoneal administration, intravenous injection, infusion, oral administration, nasal administration or other local administration, or a combination of any of the above administration methods.
[0046] The fifth aspect of the present invention provides a method for preparing the product described in the fourth aspect of the present invention, comprising the step of mixing the nanovesicles with other drugs.
[0047] Preferably, the method specifically comprises the following steps:
[0048] S1: Weigh conjugated linoleic acid, phospholipids, vitamin E polyethylene glycol succinate, and other drugs respectively to obtain a mixture, and dissolve the mixture in an organic solvent to obtain a mixed solution.
[0049] Preferably, the method further comprises:
[0050] S2: Add the mixed solution into the arginine solution and mix.
[0051] Preferably, the mass volume ratio of the mixture to the organic solvent is 60-120 mg / mL.
[0052] Preferably, the organic solvent includes at least one of anhydrous ethanol, butylene glycol and propylene glycol.
[0053] Preferably, the arginine solution is prepared by adding arginine into a solvent to obtain the arginine solution.
[0054] Preferably, the mass volume ratio of arginine to solvent is 0.1-12.5 mg / mL.
[0055] Preferably, the solvent for the arginine includes but is not limited to water and a buffer solution.
[0056] Preferably, the buffer comprises PBS buffer or HEPES buffer.
[0057] Preferably, the pH of the buffer solution is 6-8.
[0058] Preferably, the mixed solution in step S2 is added dropwise into the arginine solution.
[0059] Preferably, the mixing time in step S2 is 30 min to 60 min, the rotation speed is 500 rpm to 1000 rpm, and the temperature is 10° C. to 30° C.
[0060] The beneficial effects of the present invention are:
[0061] In order to improve the conditions for the self-assembly of conjugated linoleic acid, the present invention provides a nanovesicle constructed based on conjugated linoleic acid, specifically, conjugated linoleic acid vesicles are prepared with conjugated linoleic acid, phospholipids and vitamin E polyethylene glycol succinate, and arginine is modified on the surface to obtain conjugated linoleic acid nanovesicles Arg-CLAVs; the conjugated linoleic acid nanovesicles of the present invention have good transdermal penetration and retention behavior, and the conjugated linoleic acid nanovesicles accumulate in the hair follicles and target the hair follicles; the preparation method of the conjugated linoleic acid nanovesicles is simple, and androgenic alopecia can be treated through multiple mechanisms, and the aging problem in androgenic alopecia can be alleviated. After the conjugated linoleic acid vesicles are used as carriers and the hair loss treatment drugs are encapsulated, the obtained preparation has good therapeutic effects in male and female androgenic alopecia. BRIEF DESCRIPTION OF THE DRAWINGS
[0062] Figure 1 The particle size of nanovesicles prepared by combining different membrane materials with conjugated linoleic acid under different pH conditions.
[0063] Figure 2 Skin penetration effect of conjugated linoleic acid vesicles loaded with minoxidil.
[0064] Figure 3 The effects of conjugated linoleic acid vesicles on the proliferation (a) and migration (b, c) of human dermal papilla cells, where (c) is the image of cell migration at different time points, and (b) is the quantitative result of (c).
[0065] Figure 4 The effects of conjugated linoleic acid vesicles on the proliferation (a) and migration (b, c) of venous endothelial cells, where (c) is the image of cell migration at different time points, and (b) is the quantitative result of (c).
[0066] Figure 5 The figure shows the inhibitory effect of conjugated linoleic acid vesicles on androgen-induced hair follicle cell senescence, where A is the β-galactosidase staining result and B is the quantitative result of A.
[0067] Figure 6 Uptake of different nanovesicles loaded with coumarin 6 by human dermal papilla cells.
[0068] Figure 7 The figure shows the hair regeneration effect of conjugated linoleic acid vesicles encapsulating minoxidil on the male androgenic alopecia model, wherein (a) is a photo of the back of male androgenic alopecia model mice after administration of conjugated linoleic acid vesicles encapsulating minoxidil, (b) is the statistical score of the skin color on the back of the mice in Figure (a), and (c) is the statistical weight of the new hair on the back of the mice in Figure (a).
[0069] Figure 8The figure shows the hair regeneration effect of conjugated linoleic acid vesicles encapsulating minoxidil on the female androgenic alopecia model, wherein (a) is a photo of the back of female androgenic alopecia model mice after administration of conjugated linoleic acid vesicles encapsulating minoxidil, (b) is the statistical score of the skin color on the back of the mice in Figure (a), and (c) is the statistical weight of the new hair on the back of the mice in Figure (a).
[0070] Fig. 9 H&E staining photos of the new hair of hair loss model mice encapsulated with minoxidil conjugated linoleic acid vesicles (a) and the detection results of the hair follicle colonization depth of the new hair (b), skin thickness (c) and the number of hair follicles (d).
[0071] Fig.10 The inhibitory effect of conjugated linoleic acid vesicles loaded with finasteride on 5α-reductase.
[0072] Fig.11 The figure shows the hair regeneration effect of conjugated linoleic acid vesicles encapsulating finasteride on androgenic alopecia model mice, wherein (a) is a photo of the back of androgenic alopecia model mice after administration of conjugated linoleic acid vesicles encapsulating finasteride, and (b) is the quantitative result of hair coverage.
[0073] Specific implementation methods The following will clearly and completely describe the concept of the present invention and the technical effects produced in combination with the embodiments, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.
[0074] CLA: Conjugated Linoleic Acid.
[0075] PC: Phosphatidylcholine.
[0076] TPGS: Vitamin E polyethylene glycol succinate.
[0077] MNX: Minoxidil.
[0078] CLAVs: conjugated linoleic acid vesicles without arginine surface modification.
[0079] Arg-CLAVs: conjugated linoleic acid vesicles modified with arginine.
[0080] MNX@Arg-CLAVs: Arginine-modified conjugated linoleic acid vesicles encapsulating the hair loss treatment drug minoxidil.
[0081] Polydispersity index (PDI): An important concept in polymer science that reflects the dispersion and uniformity of nanoparticles. The smaller the value, the more uniform the particles.
[0082] β-Galactosidase: A marker of cell senescence. The higher its expression level, the higher the degree of cell senescence.
[0083] The present invention provides a nanovesicle based on conjugated linoleic acid, which can encapsulate hair loss treatment drugs for the treatment of androgenic alopecia. The nanovesicles include conjugated linoleic acid, phospholipids, vitamin E polyethylene glycol succinate and arginine. Among them, the mass ratio of conjugated linoleic acid to phospholipids to vitamin E polyethylene glycol succinate is 2:0.1-0.9:0.1-0.9:0.1-5; the phospholipids are soybean lecithin, egg yolk lecithin, hydrogenated lecithin, distearoyl phosphatidylcholine, dioleoyl lecithin, distearoyl phosphatidylethanolamine, dipalmitoyl phosphatidylethanolamine, dimyristoyl lecithin, dipalmitoyl phosphatidylcholine, dioleoyl phosphatidylcholine or more; the encapsulated hair loss treatment drugs include minoxidil, finasteride, dutasteride, etc.
[0084] Example 1: Preparation of arginine-free conjugated linoleic acid vesicles
[0085] Conjugated linoleic acid, egg yolk lecithin and vitamin E polyethylene glycol succinate were mixed at a mass ratio of 2:0.5:0.5, and the mixture was dissolved in anhydrous ethanol at a mass volume ratio of 75 mg / mL to obtain an anhydrous ethanol mother liquor. Under the conditions of a stirring speed of 1000 rpm and a stirring temperature of 30°C, the anhydrous ethanol mother liquor was added dropwise into a PBS buffer solution with a pH value of 6.5, wherein the volume ratio of the PBS buffer solution to anhydrous ethanol was 9:1; stirred for 30 minutes to obtain a conjugated linoleic acid vesicle solution (CLAVs) without arginine.
[0086] Example 2: Preparation of arginine-conjugated linoleic acid vesicles
[0087] Conjugated linoleic acid, egg yolk lecithin and vitamin E polyethylene glycol succinate were mixed at a mass ratio of 2:0.5:0.5, and then dissolved in anhydrous ethanol at a mass volume ratio of 75 mg / mL to obtain anhydrous ethanol mother liquor. Arginine was dissolved in a PBS buffer solution with a pH value of 6.5 at a mass volume ratio of 5.56 mg / mL. Under the conditions of stirring speed of 1000 rpm and stirring temperature of 30°C, the anhydrous ethanol mother liquor was added dropwise to the PBS solution containing arginine, wherein the volume ratio of PBS buffer to anhydrous ethanol was 9:1, and the mass ratio of conjugated linoleic acid to arginine was 1:1; stirred for 30 minutes to obtain a conjugated linoleic acid vesicle solution (Arg-CLAVs).
[0088] Example 3: Preparation of arginine-conjugated linoleic acid vesicles
[0089] Conjugated linoleic acid, soybean lecithin and vitamin E polyethylene glycol succinate were mixed at a mass ratio of 2:0.5:0.5, and then dissolved in anhydrous ethanol at a mass volume ratio of 75 mg / mL to obtain anhydrous ethanol mother liquor. Arginine was dissolved in a PBS buffer solution with a pH value of 6.5 at a mass volume ratio of 5.56 mg / mL. Under the conditions of stirring speed of 1000 rpm and stirring temperature of 30°C, the anhydrous ethanol mother liquor was added dropwise to the PBS solution containing arginine, wherein the volume ratio of PBS buffer solution to anhydrous ethanol was 9:1, and the mass ratio of conjugated linoleic acid to arginine was 1:1; stirred for 30 minutes to obtain a conjugated linoleic acid vesicle solution.
[0090] Example 4: Preparation of arginine-conjugated linoleic acid vesicles
[0091] Conjugated linoleic acid, egg yolk lecithin and vitamin E polyethylene glycol succinate were mixed at a mass ratio of 2:0.25:0.75, and then dissolved in anhydrous ethanol at a mass volume ratio of 75 mg / mL to obtain an anhydrous ethanol mother solution. Arginine was dissolved in a PBS buffer solution with a pH value of 6.5 at a mass volume ratio of 5.56 mg / mL. Under the conditions of stirring speed of 1000 rpm and stirring temperature of 30°C, the anhydrous ethanol mother solution was added dropwise to the PBS solution containing arginine, and the mass ratio of conjugated linoleic acid to arginine was 1:1; stirred for 30 minutes to obtain a conjugated linoleic acid vesicle solution.
[0092] Example 5: Preparation of arginine-conjugated linoleic acid vesicles
[0093] Conjugated linoleic acid, egg yolk lecithin and vitamin E polyethylene glycol succinate were mixed at a mass ratio of 2:0.75:0.25, and then dissolved in anhydrous ethanol at a mass volume ratio of 75 mg / mL to obtain anhydrous ethanol mother liquor. Arginine was dissolved in a PBS buffer solution with a pH value of 6.5 at a mass volume ratio of 5.56 mg / mL. Under the conditions of stirring speed of 1000 rpm and stirring temperature of 30°C, the anhydrous ethanol mother liquor was added dropwise to the PBS solution containing arginine, and the mass ratio of conjugated linoleic acid to arginine was 1:1; stirred for 30 minutes to obtain a conjugated linoleic acid vesicle solution.
[0094] Example 6: Preparation of conjugated linoleic acid vesicles loaded with minoxidil
[0095] Conjugated linoleic acid, egg yolk lecithin, vitamin E polyethylene glycol succinate and minoxidil were mixed at a mass ratio of 2:0.5:0.5:1.8, and then dissolved in anhydrous ethanol at a mass volume ratio of 120 mg / mL to obtain anhydrous ethanol mother liquor. Arginine was dissolved in a PBS buffer solution with a pH value of 6.5 at a mass volume ratio of 5.56 mg / mL. Under the conditions of stirring speed of 1000 rpm and stirring temperature of 30°C, the anhydrous ethanol mother liquor was added dropwise to the PBS solution containing arginine, wherein the volume ratio of PBS buffer to anhydrous ethanol was 9:1, and the mass ratio of conjugated linoleic acid to arginine was 1:1; stirred for 30 minutes to obtain conjugated linoleic acid vesicles (MNX@Arg-CLAVs) loaded with minoxidil.
[0096] Example 7: Preparation of conjugated linoleic acid vesicles loaded with finasteride
[0097] Conjugated linoleic acid, egg yolk lecithin, vitamin E polyethylene glycol succinate and finasteride were mixed at a mass ratio of 2:0.5:0.5:0.1, and then dissolved in anhydrous ethanol at a mass volume ratio of 77.5 mg / mL to obtain an anhydrous ethanol mother solution. Arginine was dissolved in PBS buffer at a mass volume ratio of 5.56 mg / mL. Under the conditions of stirring speed of 1000 rpm and stirring temperature of 30°C, the anhydrous ethanol mother solution was added dropwise to the PBS solution containing arginine, wherein the volume ratio of PBS buffer to anhydrous ethanol was 9:1, and the mass ratio of conjugated linoleic acid to arginine was 1:1; stirred for 30 minutes to obtain conjugated linoleic acid vesicles (FIN@Arg-CLAVs) loaded with finasteride.
[0098] Comparative Example 1
[0099] Conjugated linoleic acid and egg yolk lecithin were mixed at a mass ratio of 2:1, and then dissolved in anhydrous ethanol at a mass volume ratio of 75 mg / mL to obtain an anhydrous ethanol mother solution. Under the conditions of a stirring speed of 1000 rpm and a stirring temperature of 30°C, the anhydrous ethanol mother solution was added dropwise to a PBS buffer solution with a pH value of 6.5, wherein the volume ratio of the PBS buffer solution to anhydrous ethanol was 9:1; stirred for 30 minutes to obtain a conjugated linoleic acid vesicle solution without arginine.
[0100] Comparative Example 2
[0101] Conjugated linoleic acid and vitamin E polyethylene glycol succinate were mixed at a mass ratio of 2:1, and then dissolved in anhydrous ethanol at a mass volume ratio of 75 mg / mL to obtain an anhydrous ethanol mother liquor. Under the conditions of a stirring speed of 1000 rpm and a stirring temperature of 30°C, the anhydrous ethanol mother liquor was added dropwise to a PBS buffer solution with a pH value of 6.5, wherein the volume ratio of the PBS buffer solution to anhydrous ethanol was 9:1; stirred for 30 minutes to obtain a conjugated linoleic acid vesicle solution without arginine.
[0102] Comparative Example 3
[0103] Conjugated linoleic acid, lecithin and vitamin E polyethylene glycol succinate were mixed at a mass ratio of 2:0.5:0.5, and then dissolved in anhydrous ethanol at a mass volume ratio of 75 mg / mL to obtain an anhydrous ethanol mother solution. Under the conditions of a stirring speed of 1000 rpm and a stirring temperature of 30°C, the anhydrous ethanol mother solution was added dropwise to a PBS buffer solution with a pH value of 6.5, wherein the volume ratio of the PBS buffer solution to anhydrous ethanol was 9:1; stirred for 30 minutes to obtain a conjugated linoleic acid vesicle solution without arginine.
[0104] Effect Example 1
[0105] Conjugated linoleic acid vesicle solutions (CLA:PC:TPGS) were prepared according to the method in Example 1, wherein the pH of the PBS buffer used was 6.0, 6.5, 7.0, 7.5, and 8.0, respectively.
[0106] Conjugated linoleic acid vesicle solutions (CLA:TPGS) were prepared according to the method in Comparative Example 2, wherein the pH values of the PBS buffer used were 6.0, 6.5, 7.0, 7.5, and 8.0, respectively.
[0107] Conjugated linoleic acid vesicle solutions (CLA:PC) were prepared according to the method in Comparative Example 1, wherein the pH values of the PBS buffer used were 6.0, 6.5, 7.0, 7.5, and 8.0, respectively.
[0108] The particle size and polydispersity index of the three vesicle solutions were measured. The results are shown in Figure 1 The results show that the particle size and polydispersity index of the conjugated linoleic acid vesicles prepared according to the method in Example 1 are smaller than those of the vesicles prepared in Comparative Examples 1 and 2, indicating that the quality of the conjugated linoleic acid vesicles prepared in Example 1 is better.
[0109] Effect Example 2
[0110] According to the method in Example 1, a PBS buffer solution with a pH value of 6.5 was used to prepare a conjugated linoleic acid vesicle solution (CLAVs) without arginine modification.
[0111] According to the method in Example 2, arginine-modified conjugated linoleic acid vesicle solution (Arg-CLAVs) was prepared using PBS buffer with a pH value of 6.5.
[0112] The particle size and polydispersity index of two different vesicle solutions were measured, and the results are shown in Table 1 ;
[0113] Table 1
[0114] prescription Particle size (nm) Polydispersity Index CLAVs 201.2±1.1 0.136±0.028 Arg-CLAVs 206.3±3.1 0.113±0.012
[0115] The results showed that the conjugated linoleic acid vesicles Arg-CLAVs with arginine surface modification prepared in Example 2 had a smaller polydispersity index than the vesicles CLAVs in Example 1 without arginine surface modification, indicating that the Arg-CLAVs were more uniform and the vesicle quality was better.
[0116] Effect Example 3
[0117] The treated pigskin was washed and dried, cut to the required size, and fixed in the transdermal diffusion cell. Physiological saline containing 40% PEG-400 was added to the receiving cell and balanced at 32°C and 250rpm for 30min. MNX@Arg-CLAVs was prepared according to Example 6. At the same time, minoxidil was weighed and dissolved in ethanol-propylene glycol-PBS buffer (3:5:2, v / v) to obtain MNX tincture. 500μL MNX@Arg-CLAVs or MNX tincture was added to the supply cell, and each group was repeated 5 times in parallel. At a specific time point, 1mL of receiving solution was taken out from the receiving cell, filtered, and the cumulative penetration of minoxidil was determined by HPLC.
[0118] At a specific time point, remove the transdermal diffusion cell, discard the excess liquid, and remove the pig skin. Wash the pig skin with saline, wipe off the water, and tear the stratum corneum 15 times with transparent tape to remove the stratum corneum. Apply an appropriate amount of cyanoacrylate glue on the epidermis of the pig skin, cover it with transparent tape, and press the glue to penetrate into the hair follicles. After the glue is completely dry, tear off the transparent tape and soak the tape in methanol, ultrasonically extract, filter, and use HPLC to determine the minoxidil content in the hair follicles. Cut the pig skin into pieces and soak it in methanol, ultrasonically extract, filter, and use HPLC to determine the skin retention of minoxidil.
[0119] The results are as follows Figure 2 As shown, the results show that the conjugated linoleic acid vesicles MNX@Arg-CLAVs loaded with minoxidil prepared in Example 6 have a faster skin penetration rate, a greater retention in the skin, and a higher degree of accumulation in the hair follicles than the commonly used minoxidil tincture Mandi, and have hair follicle targeting, indicating that MNX@Arg-CLAVs can enter the skin faster, form a drug reservoir in the skin, and take effect continuously, while being able to act on the hair follicles at the lesion site.
[0120] Effect Example 4
[0121] Human dermal papilla cells were seeded in 96-well plates. After overnight attachment, conjugated linoleic acid (CLA), Arg-CLAVs and minoxidil were diluted to the desired concentrations with culture medium, and 100 μL of drug-containing culture medium was added to each well. The drug-free culture medium was used as the negative control group, and minoxidil with a final concentration of 20 μg / mL was used as the positive control group. The final concentration of CLA and Arg-CLAVs was 200 μg / mL. Each group was repeated 6 times in parallel. After 24 hours of incubation at 37°C in the dark, the absorbance at 450 nm was measured with an enzyme reader to calculate the cell proliferation rate.
[0122] Human dermal papilla cells were seeded in a 6-well plate. After growing to 80% to 90%, three vertical lines were drawn vertically with a pipette tip, and the cells were washed with PBS. The drug was diluted to the required concentration with culture medium, and the medium without drug was used as the negative control group, and minoxidil was used as the positive control group. Each group was repeated three times in parallel. The final concentration of CLA, CLAVs and Arg-CLAVs was 200μg / mL, and the final concentration of minoxidil was 20μg / mL. The cells were cultured in an incubator. At 0, 24, and 48h, photos of the scratches at fixed positions were taken to calculate the cell migration rate.
[0123] The results showed that the conjugated linoleic acid vesicles Arg-CLAVs prepared in Example 2 can promote the proliferation and migration of human hair papilla cells and contribute to the regeneration of hair follicles; compared with CLAVs without arginine surface modification, Arg-CLAVs have a better effect in promoting cell migration ( Figure 3 ).
[0124] Effect Example 5
[0125] Human umbilical vein endothelial cells were seeded in 96-well plates. After overnight attachment, conjugated linoleic acid (CLA), Arg-CLAVs and minoxidil were diluted to the desired concentrations with culture medium, and 100 μL of drug-containing culture medium was added to each well. The drug-free culture medium was used as the negative control group, and minoxidil with a final concentration of 20 μg / mL was used as the positive control group. The final concentration of CLA and Arg-CLAVs was 50 μg / mL. Each group was repeated 6 times in parallel. After 24 hours of incubation at 37°C in the dark, the absorbance at 450 nm was measured with an enzyme reader to calculate the cell proliferation rate.
[0126] Human umbilical vein endothelial cells were seeded in a 6-well plate. After growing to 80% to 90%, three vertical lines were drawn vertically with a pipette tip, and the cells were washed with PBS. The drug was diluted to the required concentration with culture medium, and the medium without drug was used as the negative control group, and minoxidil was used as the positive control group. Each group was repeated three times in parallel. The final concentration of CLA, CLAVs and Arg-CLAVs was 50μg / mL, and the final concentration of minoxidil was 20μg / mL. The cells were cultured in an incubator. At 0 and 24h, photos of the scratches at fixed positions were taken to calculate the cell migration rate.
[0127] The results showed that the conjugated linoleic acid vesicles Arg-CLAVs prepared in Example 2 can promote the proliferation and migration of venous endothelial cells, help the formation of blood vessels around hair follicles, restore the nutrient supply of hair follicles, and promote hair regeneration. Compared with CLAVs without arginine surface modification, Arg-CLAVs have a better effect in promoting cell migration ( Figure 4 )
[0128] Effect Example 6
[0129] Human dermal papilla cells were seeded in 12-well plates and cultured overnight. CLA, CLAVs and Arg-CLAVs were diluted with culture medium, and the original culture medium was replaced and cultured for 24 hours. The next day, the dihydrotestosterone stock solution was diluted with culture medium, mixed with culture medium containing CLA, CLAVs and Arg-CLAVs, and the culture medium was replaced again. The final concentration of dihydrotestosterone was 10μM, and the final concentrations of CLA, CLAVs and ArgCLAVs were all 200μg / mL. The negative control group was cultured only with culture medium, and the positive control group was cultured only with culture medium containing dihydrotestosterone. Each group was repeated 3 times in parallel. After 48 hours, the cells were stained with a β-galactosidase staining kit for 24 hours, observed in a cell imaging system, images were taken, and the positive rate of β-galactosidase was calculated.
[0130] The results showed that the conjugated linoleic acid vesicles Arg-CLAVs prepared in Example 2 can effectively reduce the expression of β-galactosidase, a marker of cell senescence caused by androgen, which means that it can alleviate the senescence of hair follicle cells caused by androgen, restore the health of hair follicles, and better treat androgenic alopecia ( Figure 5 ).
[0131] Effect Example 7
[0132] Human dermal papilla cells were seeded in a laser confocal dish and cultured overnight. CLAVs and Arg-CLAVs encapsulated with coumarin 6 were prepared and diluted with culture medium. Free coumarin 6 or CLAVs encapsulated with coumarin 6 or Arg-CLAVs encapsulated with coumarin 6 were added to the cells and incubated at 37°C for 4 hours in the dark, then the culture medium was discarded and washed with PBS. The cell nuclei were then stained with DAPI and incubated at 37°C for 10 minutes. After staining, the cells were washed with PBS, and the cells were placed under a laser confocal microscope for observation to calculate the amount of coumarin 6 taken up by the cells.
[0133] The results showed that the conjugated linoleic acid vesicles Arg-CLAVs prepared in Example 2 can significantly promote the uptake of human hair papilla cells; compared with CLAVs without arginine surface modification, Arg-CLAVs have a better effect in promoting cell uptake, indicating that Arg-CLAVs can enter cells faster to exert their effects ( Figure 6 ).
[0134] Effect Example 8
[0135] Male C57BL / 6J mice (6-8 weeks) were randomly divided into 5 groups, 5 mice in each group. After anesthesia, the mice were shaved and depilatory cream was used to remove hair. After one day of recovery, the mice were subjected to the experiment. The control group was treated with saline only, the model group was first applied with testosterone solution, and then saline was applied after waiting for 30 minutes; each experimental group was first applied with testosterone solution, and then the drug solution was applied after waiting for 30 minutes. The drug solution was 5% minoxidil tincture (Mandi, containing 50 mg / mL of minoxidil) or Arg-CLAVs (5 mg / mL) or MNX@Arg-CLAVs (5 mg / mL, containing 4.5 mg / mL of minoxidil). Testosterone was dissolved in ethanol-saline solution (1:1, V / V) at a concentration of 5 mg / mL. After the start of drug administration, photos of the depilatory area on the back of the mice were taken on days 1, 13, 17, 21, and 27. On days 13 and 17, the skin color of the depilatory area of the mice was scored. On the 27th day of the experiment, the mice were anesthetized, and the newly grown hair in the hair loss area was shaved off to obtain the weight of the newly grown hair.
[0136] The compositions of the commercially available 5% minoxidil tincture and MNX@Arg-CLAVs are shown in Table 2. It can be seen that the content of minoxidil in the minoxidil-loaded conjugated linoleic acid vesicles MNX@Arg-CLAVs prepared in Example 6 is about one-tenth of that in the commercially available minoxidil tincture Mandi, and the content of organic solvent is reduced by about 7 times compared with that in the minoxidil tincture, and does not contain the irritating raw material propylene glycol.
[0137] Table 2
[0138]
[0139] The results of animal experiments also further showed that the minoxidil-loaded conjugated linoleic acid vesicles MNX@Arg-CLAVs prepared in Example 6 can significantly promote hair regeneration in the male androgenic alopecia model. The skin on the back of the mice darkens faster and the weight of the new hair is heavier, which is better than the common 5% minoxidil tincture Mandi ( Figure 7 ).
[0140] Effect Example 9
[0141] Female C57BL / 6J mice (6-8 weeks) were randomly divided into 4 groups, 4 mice in each group. After the mice were anesthetized, the hair on the back was shaved and depilatory cream was used to remove hair. After the mice recovered for one day, the mice were subjected to the experiment. The control group was treated with normal saline only, the model group was first applied with testosterone solution, and then normal saline was applied after waiting for 30 minutes; each experimental group was first applied with testosterone solution, and then the drug solution was applied after waiting for 30 minutes. The drug solution was 5% minoxidil tincture (Mandi, containing 50 mg / mL of minoxidil) or MNX@Arg-CLAVs (5 mg / mL, containing 4.5 mg / mL of minoxidil). Testosterone was dissolved in ethanol-normal saline solution (1:1, V / V) at a concentration of 5 mg / mL. After the start of drug administration, photos of the depilatory area on the back of the mice were taken on days 1, 13, 17, 26, and 34. On days 13 and 17, the skin color of the depilatory area of the mice was scored. On the 34th day of the experiment, the mice were anesthetized, the newly grown hair in the hair loss area was shaved off, and the weight of the newly grown hair was measured.
[0142] The experimental results show that the minoxidil-loaded conjugated linoleic acid vesicles MNX@Arg-CLAVs prepared in Example 6 also have a good therapeutic effect in the female androgenic alopecia model, and can significantly promote the regeneration of hair and the darkening speed of the back skin of mice. The weight of the newly grown hair is higher, and the therapeutic effect is still better than the common 5% minoxidil tincture Mandi ( Figure 8 ).
[0143] Effect Example 10
[0144] On the 27th day of the experiment, male mice were anesthetized and killed. The skin of the depilated area on the back was taken, wrapped in tin foil and fixed with 4% paraformaldehyde. The tissue was then embedded in paraffin, sliced, and stained with H&E. The slices were observed by a cell imaging system, and images were taken to evaluate the depth of hair follicle colonization, skin thickness, and number of hair follicles.
[0145] The results showed that the minoxidil-loaded conjugated linoleic acid vesicles MNX@Arg-CLAVs prepared in Example 6 can effectively increase the follicle colonization depth of new hair, skin thickness and the number of hair follicles, so that the hair can grow healthily and vigorously ( Fig. 9 ).
[0146] Effect Example 11
[0147] 5α-reductase was extracted from rat prostate. 0.25 mL of phosphate buffer, 0.70 mL of enzyme extract, 0.1 mL of testosterone solution (0.5 mg / mL), 0.35 mL of NADPH solution (1 mg / mL), and 0.6 mL of sample solution (finasteride solution: 0.25 mg / mL, or FIN@Arg-CLAVs in Example 7) were added to a centrifuge tube. The enzyme extract in the blank control group was replaced with phosphate buffer, and the sample solution in the negative control group was sterile saline. The sample tube was reacted at 37°C for 30 minutes, and then dichloromethane was added to terminate the reaction. The sample tube was centrifuged at 5000 rpm for 10 minutes, the organic phase was evaporated, and the residue was dissolved in methanol. The residual testosterone was determined by HPLC and the inhibition rate of 5α-reductase was calculated (n=6).
[0148] The results showed that the finasteride-loaded conjugated linoleic acid vesicles FIN@Arg-CLAVs prepared in Example 7 could effectively inhibit the activity of 5α-reductase, and the inhibition rate was significantly higher than that of the finasteride solution of the same concentration ( Fig.10 ).
[0149] Effect Example 12
[0150] Male C57BL / 6J mice (6-8 weeks) were randomly divided into 4 groups, 4 mice in each group. After the mice were anesthetized, the hair on the back was shaved and depilatory cream was used to remove hair. After the mice recovered for one day, the mice were subjected to the experiment. The control group was treated with normal saline only; the model group was first applied with testosterone solution, and then normal saline was applied after waiting for 30 minutes; each test group was first applied with testosterone solution, and then the drug solution was applied after waiting for 30 minutes. The drug solution was 0.25 mg / mL finasteride or FIN@Arg-CLAVs in Example 7. Testosterone was dissolved in ethanol-normal saline solution (1:1, V / V) at a concentration of 5 mg / mL. After the start of administration, photos of the depilatory area on the back of the mice were taken on days 1, 6, 13, 17, 22, 26, and 31. On day 31, the hair coverage of the depilatory area of the mice was calculated.
[0151] The results showed that the finasteride-loaded conjugated linoleic acid vesicles FIN@Arg-CLAVs prepared in Example 7 had a good therapeutic effect in the male androgenic alopecia model, and could significantly promote the regeneration of hair and the darkening speed of the back skin of mice. The hair coverage rate on the 31st day was significantly better than that of the finasteride solution with the same concentration ( Fig.11 ).
[0152] The above specific implementations have been described in detail for the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. A nanovesicle, wherein the raw materials for preparing the nanovesicle include conjugated linoleic acid, phospholipids and vitamin E polyethylene glycol succinate.
2. The nanovesicle according to claim 1, characterized in that The mass ratio of the conjugated linoleic acid, phospholipid and vitamin E polyethylene glycol succinate is 2:0.1-0.9:0.1-0.
9.
3. The nanovesicle according to claim 1, characterized in that The phospholipids are one or more of soybean lecithin, egg yolk lecithin, hydrogenated lecithin, distearoylphosphatidylcholine, dioleoyl lecithin, distearoylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine, dimyristoyl lecithin, dipalmitoylphosphatidylcholine and dioleoylphosphatidylcholine.
4. The nanovesicle according to any one of claims 1 to 3, characterized in that The raw materials for preparing the nanovesicles also include arginine, and the mass ratio of the conjugated linoleic acid, phospholipids, vitamin E polyethylene glycol succinate and arginine is 2:0.1-0.9:0.1-0.9:0.1-5.
5. The method for preparing the nanovesicles according to any one of claims 1 to 4, comprising mixing conjugated linoleic acid, lecithin and vitamin E polyethylene glycol succinate and dissolving them in an organic solvent to obtain a solution A; Preferably, the method further comprises: adding solution A to the arginine solution and mixing.
6. Use of the nanovesicles according to any one of claims 1 to 4 in the preparation of products for hair growth and / or prevention and treatment of hair loss; preferably, the hair loss includes partial hair loss, total hair loss or systemic hair loss caused by androgenic alopecia, seborrheic alopecia, anagen effluvium, telogen effluvium, drug-induced alopecia, alopecia areata, tinea capitis or hypotrichosis.
7. A product comprising the nanovesicle according to any one of claims 1 to 4.
8. The product according to claim 7, characterized in that The product also includes one or more other drugs for treating hair loss; preferably, the other drugs include minoxidil, finasteride, dutasteride, spironolactone tablets, cyproterone acetate and / or clobetasol propionate or a pharmaceutically acceptable salt thereof.
9. The product according to claim 8, characterized in that The mass ratio of the conjugated linoleic acid and other drugs in the nanovesicles is 1:0.01-1.
5.
10. The product according to any one of claims 7 to 9, characterized in that: The products include medicines and daily chemicals; preferably, the daily chemicals include hair growth liquid, hair tonic, hair conditioner, shampoo head, hair cleaning foam, hair oil, hair dryer, hair dye, hair gel, hair glaze, hair moisturizer, hair mask, hair cream, eyebrow growth agent, eyelash growth agent, eyelash nutrition agent; Preferably, the product further comprises auxiliary materials; Preferably, the dosage form of the product includes granules, granules, capsules, tablets, sprays, lotions, ointments, patches, injections, emulsions, aerosols, drops, gels, microneedles, controlled-release agents, and sustained-release agents; Preferably, the administration of the product includes subcutaneous administration, intramuscular administration, intraperitoneal administration, intravenous injection, infusion, oral administration, nasal administration or other local administration, or a combination of any of the above administration methods.
Citation Information
Patent Citations
Composition, preparation and application of magnetic liposome vesicles
CN107998978A
Stabilized Nanovesicle Containing Oleaginous ComponentsAnd Transparent Cosmetic Composition Comprising theSame
KR1020070071500A
Formulations of phospholipid comprising omega fatty acids
US20210307349A1
Tocopherol succinate derivatives and compositions
WO2002076970A2
Cited By
Cacumen biotae vesicle as well as preparation method and application thereof
CN120966735A
